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Inhibition of Cellular Respiration by Doxorubicin
Zhimin Tao,† Henry G. Withers,‡ Harvey S. Penefsky,§ Jerry Goodisman,*,† and
Abdul-Kader Souid*,‡
Department of Chemistry, Syracuse UniVersity, CST, 1-014, Syracuse, New York 13244-4100, Department of
Pediatrics, Upstate Medical UniVersity, State UniVersity of New York, Syracuse, New York 13210-2375, and
Public Health Research Institute, 225 Warren Street, Newark, New Jersey 07103
ReceiVed NoVember 12, 2005
Doxorubicin executes apoptosis, a process known to produce leakage of cytochromeand opening of
the mitochondrial permeability transition pores. To define the loss of mitochondrial function by apoptosis,
we monitored cellular respiration during continuous exposure to doxorubicin. A phosphorescence analyzer
capable of stable measurements over at least 5 h was used to measure [O2]. In solutions containing
glucose and cells, [O2] declined linearly with time, showing that the kinetics of oxygen consumption
was zero order. Complete inhibition of oxygen consumption by cyanide indicated that oxidations occurred
in the respiratory chain. A decline in the rate of respiration was evident in Jurkat and HL-60 cells exposed
to doxorubicin. The decline was abrupt, occurring after about 2 h of incubation. The inhibition was
concentration-dependent and was completely blocked by the pan-caspase inhibitor benzyloxycarbonyl-
Val-Ala-Asp-fluoromethyl ketone. Respiration in resistant HL-60/MX2 cells, characterized by an altered
topoisomerase II activity, was not inhibited by doxorubicin. A decline in cellular ATP was measured in
Jurkat cells after 2-4 h of incubation with 20µM doxorubicin, paralleling the decline in respiration rate.
Thus, cells incubated with doxorubicin exhibit caspase-mediated inhibition of oxidative phosphorylation.
Introduction
Doxorubicin, an anthracycline antibiotic, is a widely used
anticancer drug (1). This agent intercalates with DNA and
produces DNA breaks by stimulating topoisomerase II-cleavable
complex formation (2, 3). Doxorubicin also targets the mito-
chondria, impairing cellular respiration (4-7). In the cell, the
quinone moiety of doxorubicin is reduced to semiquinone
radicals, generating reactive oxygen species, which directly
damage cell organelles (6). Oxidative damage produced by the
drug is partially mediated by the doxorubicin-Fe(III) complex
(8). The outcome of these events is cell death, primarily by
apoptosis (9, 10).
Apoptosis is executed by a series of cysteine proteases, termed
caspases. Caspase activation leads to mitochondrial dysfunction
(11). The mitochondrial perturbation includes opening of the
permeability transition pores (PTP)1 (12). The PTPs, formed at
contact sites between the inner and the outer mitochondrial
membranes, are composed primarily of cyclophilin D (inhibited
by cyclosporine A), the adenine nucleotide translocator (inhib-
ited by bongkrekic acid), and the voltage-dependent anion
channel. The PTPs permit passage of protons (which collapses
the mitochondrial membrane potential,∆ψ, and leads to
uncoupling of oxidative phosphorylation) and low molecular
weight apoptogenic proteins (e.g., cytochromec, which de-
creases mitochondrial oxygen consumption). It has been sug-
gested that the mitochondrial perturbations are transient (11).
Clinically, the maximum concentration of plasma doxorubicin
after 30-60 mg/m2 iv bolus dosing is 3-10 µM, with t1/2R of
5.0 ( 2.5 min, t1/2â 1.9 ( 0.6 h, andt1/2γ 39 ( 19 h (13).
However, cellular doxorubicin levels are usually 30-100-fold
higher than those of the plasma (13). The serious side effects
of doxorubicin that limit its clinical use include cardiomyopathy,
which is, at least partially, a result of drug-induced mitochondrial
impairment (4).
Although many of the processes involved in drug-induced
apoptosis have been identified, a full understanding of apoptosis
requires knowledge of the temporal relationships between them.
This necessitates direct measurement of the time course of
individual processes, such as respiration. Here, we measure the
effect of doxorubicin on cellular mitochondrial oxygen con-
sumption during doxorubicin exposure. The rate of respiration
is unchanged for about 2 h, after which it decreases abruptly.
We also measure cellular ATP levels, changes in which parallel
changes in respiration. The results show that cyanide-sensitive
oxidative phosphorylation is inhibited in cells undergoing
apoptosis in response to doxorubicin.
Materials and Methods
Chemicals. Solutions of doxorubicin HCl (3.45 mM) were
purchased from GensiaSicor Pharmaceuticals (Irvine, CA). A
lyophilized powder of caspase inhibitor I (zVAD-fmk, m.w. 467.5)
was purchased from Calbiochem (San Diego, CA). The Pd(II)
complex ofmeso-tetra(4-sulfonatophenyl)tetrabenzoporphyrin (Pd
phosphor sodium salt) was purchased from Porphyrin Products
(Logan, UT). Dulbecco’s phosphate-buffered saline (PBS, without
calcium or magnesium), fetal bovine serum, and RPMI-1640
medium (10-040) with L-glutamine (pH 7.15( 0.1) were
purchased from Mediatech (Herndon, VA). Human (promyelocytic)
leukemia (HL-60), HL-60/MX2 (CRL-2257, a mitoxantrone-
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resistant derivative of the HL-60 cell line), and Jurkat clone E6-1
human acute T cell leukemia (TIB-152) cell lines were purchased
from American Tissue Culture Collection (Manassas, VA). A
luciferin-luciferase mixture (0.2 mg of luciferin and 22000 units
of luciferase per vial, stored at-20 °C) and ATP (2µmol per vial,
stored at-20 °C) were purchased from Chrono-Log (Havertown,
PA). The remaining reagents were purchased from Sigma-Aldrich
(St. Louis, MO).
Solutions. A 2 mM solution of the Pd phosphor was prepared
by dissolving the powder at 2.5 mg/mL in dH2O and was stored at
-20 °C. Aqueous solutions of ATP (0.4 mM) were prepared in 10
mM Tris-HEPES (pH 7.5) and stored at-70 °C. The final
concentration was determined by absorbance at 259 nm using a
molar extinction coefficient of 15400 (14). A working solution of
ATP (4 µM) was prepared fresh in a solution containing 0.1 M
Tris-HEPES (pH 7.5), 5 mM MgCl2, and 0.1% fat-free bovine
serum albumin. A lyophilized powder containing luciferin (0.2 mg;
molecular weight, 280) and luciferase (22000 units) was freshly
dissolved in 1.25 mL of PBS, protected from light, and placed on
ice. The final concentration of luciferin (570µM) was determined
from its absorbance at 327 nm, using the molar extinction coefficient
of 18000 (14). NaCN solution was prepared at 2.0 M and brought
to pH∼7.5 with 12 N HCl. The zVAD-fmk solution was made by
dissolving 1.0 mg in 1.0 mL of DMSO (final concentration,∼2.14
mM) and was stored at-20 °C.
Cells.HL-60, the resistant clone HL-60/MX2, and human T-cell
lymphoma (Jurkat) cells were maintained in suspension cultures
as described (24). The resistance of HL-60/MX2 exhibits an altered
topoisomerase II catalytic activity and reduced levels of topo-
isomerase IIR andâ proteins (15). Cell count and viability were
determined by light microscopy, using a hemacytometer under
standard trypan blue staining conditions.
Incubation with Drugs. Cells were suspended at 106 cells/mL
in media (containing 6.0 mM Na2HPO4 and 10 mM glucose; pH
∼7.4), 10% fetal bovine serum, 2.0µM Pd phosphor, and 1% fat-
free serum bovine albumin and placed at 37°C. The drugs (e.g.,
doxorubicin, zVAD-fmk, and NaCN) were then added. For each
condition, 1.0 mL (final volume after all additions, typically<20
µL) of the cell suspension was placed in 1.0 mL glass vials (8 mm
clear vials, Krackler Scientific, Albany, NY). The vials were sealed
with a crimp top aluminum seal (using a Wheaton hand crimper;
Fisher Scientific) and placed in the instrument for oxygen measure-
ments at 37°C. Mixing was accomplished with the aid of parylene-
coated stirring bars (1.67 mm× 2.01 mm × 4.8 mm; V&P
Scientific, Inc., San Diego, CA).
Oxygen Consumption.Cellular respiration was measured at 37
°C (16-19). The substrate was glucose. The rate of respiration was
determined as the negative slope of the curve of [O2] vs t (zero-
order rate constant,k, in µM O2 min-1 per 106 cells). [O2] in the
suspension was determined, as a function of time, using the
phosphorescence of Pd(II)meso-tetra(4-sulfonatophenyl)tetraben-
zoporphyrin. The phosphorescence decay of the probe was char-
acterized by a single exponential, with the reciprocal of the
phosphorescence decay time (τ) being linear in [O2], according to
τo/τ ) 1 + τo kq [O2]. Here, τ is the lifetime in the presence of
oxygen;τo is the lifetime in the absence of oxygen; andkq is the
second-order oxygen-quenching rate constant. The drift of the Pd
phosphor solution without cells wase0.18µM O2 min-1. zVAD-
fmk alone had no effect on the value ofk.
Samples were exposed to light flashes (10/s) from a pulsed light-
emitting diode array with peak output at 625 nm (OTL630A-5-
10-66-E, Opto Technology, Inc., Wheeling, IL). Emitted phospho-
rescent light was detected by a Hamamatsu photomultiplier tube
(#928) after first passing it through a wide-band interference filter
centered at 800 nm. The amplified phosphorescence decay was
digitized at a rate of 1 MHz by a 20 MHz A/D converter (Computer
Boards, Inc.). Two hundred fifty samples were collected from each
decay curve, and the data from 10 consecutive decay curves were
averaged for calculation ofτ. The instrument was calibrated using
ascorbate and ascorbate oxidase as described below (16).
Phosphorescence measurements on cell suspensions were always
carried out simultaneously on 4-6 samples from the same cell
culture in order to minimize errors due to variation in culture
preparation. Meaningful phosphorescence measurements could not
be made until about 30 min after the addition of doxorubicin. This
time was required for processing samples, including filling the glass
vials, eliminating air bubbles, cleaning and warming the vials to
37 °C, placing them in the instrument, and starting the program.
Measurements were then made sequentially on the different
samples. The missing points for early times did not affect
comparison of the rates of respiration among the different samples
of cells from the same culture. Usually, each of the 4-6 samples
represented a different condition. The measurements were done
simultaneously on these multiple samples from the same culture
preparation. Because of variability between culture preparations,
it is not meaningful to comparek values obtained with different
preparations. Onlyk values for different conditions using the same
preparation are comparable. When duplicate measurements for the
same condition and the same preparation were performed, the
coefficient of variation ink was less than 10%.
In some measurements, increasing the doxorubicin concentration
appeared to be associated with increased values of [O2]. This is
believed to be an artifact of the measurement method, associated
with the red color of doxorubicin (since the excitation wavelength
for the Pd phosphor is 625 nm). The red light scattered by
doxorubicin affects the measured phosphorescence decay curve,
which is fit to an exponentialAe-t/τ, leading to a lowered value of
τ (see equation below) and a higher calculated [O2]. Absorbance
measurements in the presence of cells showed that the doxorubicin
concentration did not change materially during experiments lasting
up to 5 h. Thus, the artifact associated with the red color does not
affect the time dependence of [O2].
ATP Content. Acid extracts were prepared by adding 200µL
of 10% perchloric acid to pellets containing 106 cells. The mixture
was sonicated on ice for 30 s, and the supernatant was collected
by centrifugation and neutralized by adding 200µL of 2.0 M KOH.
The sample was incubated on ice for 15 min, and precipitated
KClO4 was removed by centrifugation. The ATP content in the
resulting supernatant was determined immediately.
The luciferin-luciferase bioluminescence system was used to
determine cellular ATP (14, 20). Luminescence was measured at
37 °C using a luminometer (Chrono-Log Corp.) connected to a
Chrono-log AGGRO/LINK interface. The data were exported into
Microsoft Excel and analyzed as described below. The reaction
mixture contained, in a final volume of 0.4 mL, 0.1 M Tris-HEPES
(pH 7.6), 5 mM MgCl2, 0.1% fat-free bovine serum albumin, and
ATP (40-240 pmol) or cellular acid extracts (5-10 µL). The
reaction was started by rapidly injecting 10µL of luciferin/luciferase
mixture (5 nmol of luciferin and 176 units of luciferase) from a 50
µL Hamilton syringe into 0.4 mL of rapidly stirred assay mixture.
Light emission was measured every half second for 600 s, and
the resulting intensity vst curve was fit to an exponential,Ae-kt.
As shown below, the [ATP] can be obtained from the value of the
exponential parameterk. However, [ATP] is proportional tok only
for concentrations below∼0.15µM; thus, it was necessary to dilute
some cellular extracts before the measurements. Furthermore,
variations in the luciferin/luciferase used required that each batch
be calibrated against standard solutions before use in ATP measure-
ments.
Results
Phosphorescence Calibration.Figure 1A is an example of
a titration of dissolved O2 with ascorbic acid in the presence of
ascorbate oxidase. Two milliliters of Pd phosphor solution
(containing media, 10% fetal bovine serum, 2.0µM Pd
phosphor, 1% fat-free albumin, and 1.25 units of ascorbate
oxidase, final pH∼7.3) was titrated at 37°C by addition of 10
µL aliquots of 10 mM ascorbate. [O2] was measured electro-
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chemically, as percent of saturationS. This was converted to
molar concentrationC according to
where 0.21× (1 atm) is the partial pressure of oxygen in the
atmosphere, 55.5 M is the molarity of water, andKH is the
Henry’s Law constant for dissolved oxygen in water at 37°C,
5.211× 109 Pa. The calculated values ofC are plotted in Figure
1A.
[O2] decreased linearly (r2 > 0.991) with ascorbate added.
The slope of the line (-0.668) may be compared with the
theoretical stoichiometry (mol of O2 consumed per mol of
ascorbate added) of 0.5. The discrepancy is due to the fact that
the total molarity of the solution and the Henry’s Law constant
used in the equation above are appropriate for pure water, but
the values appropriate for our solutions are not known.
Multiplication of the above equation by (0.5/0.668) converted
percent saturationS, as measured electrochemically, to [O2]
according toC ) S(1.696µM).
Phosphorescence lifetimes (τ) were measured in a series of
ascorbate/ascorbate oxidase solutions (16), simultaneously with
electrochemical measurement of [O2]. Results are shown in
Figure 1B as a plot of 1/τ vs [O2], which is linear (r2 ) 0.987)
as it should be according to the theoretical relation:
The value of the quenching constantkq, determined from the
slope of the plot, was 96.1( 1.2 µM-1 s-1. The value of 1/τo,
from the intercept, was (10087( 156) s-1. The above equation
was used to calculate [O2] from measured values ofτ.
Figure 1. (A) Titration of dissolved O2 in Pd phosphor solution by
ascorbate in the presence of ascorbate oxidase (using the O2 el ctrode).
Two milliliters of Pd phosphor solution containing media, fetal bovine
serum, albumin, and ascorbate oxidase (final pH∼7.3) was titrated at
37 °C by addition of 10µL aliquots of 10 mM ascorbate. The apparent
stoichiometry (moles of O2 consumed per moles of ascorbate added)
was 0.67 (r2 > 0.991). (B) The reciprocal of measured phosphorescence
lifetime (1/τ) is plotted vs electrochemically measured [O2] in solution
(two sets of experiments). The equation 1/τ ) 1/τ0 + kq[O2] is used to
convert measured phosphorescence lifetimeτ to [O2]. The quenching
constant (kq), obtained from the slope of the best-fit straight line (r2 >
0.92), is (152( 11) × 106 M-1 s-1. The value of 1/τ0, from the
intercept, is 10087( 156 s-1.
C ) S
0.21× (1.013× 105 Pa)× 55.5 M
100× KH
Figure 2. Doxorubicin effect on Jurkat cell respiration. (A) Jurkat
cells were suspended at 106 cells per mL media, 10% fetal bovine serum,
2 µM Pd phosphor, and 1% albumin. One milliliter of each cell
suspension was placed in a 1 mL glass vial, which was sealed and
placed in the instrument for [O2] measurements. Minute zero corre-
sponds to the addition of doxorubicin. Diamonds, untreated cells with
best-fit line; triangles and circles, cells treated with 5 and 10µM
doxorubicin, respectively. Lines are drawn parallel to best-fit line for
untreated cells. (B) Modulation of doxorubicin effect of cellular
respiration by zVAD-fmk. Jurkat cells were processed as above. Minute
zero corresponds to the addition of 20µM doxorubicin. Diamonds,
cells plus DMSO with linear fit; squares, cells plus 20µM doxorubicin
plus DMSO with line parallel to previous linear fit; and triangles, cells
plus 20µM doxorubicin plus 20µM zVAD-fmk with best-fit line. (C)
Inhibitory effect of NaCN. Jurkat cells were processed as above. Minute
zero corresponds to the addition of 20µM doxorubicin and 10 mM
cyanide. Squares, cells plus 10 mM NaCN with best-fit line (slope)
-0.128); circles, cells plus 20µM doxorubicin with best-fit line after
120 min (slope) -0.20); and filled squares, cells plus 20µM
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Effect of Doxorubicin on Cellular Respiration. Jurkat cell
respiration in the presence of 5 and 10µM doxorubicin is shown
in Figure 2A. For untreated cells, respiration was constant and
[O2] was a linear function of time (slope) -1.70µM O2/min/
106 cells). The rate constantk is the negative of the slope. For
treated cells, the rate of cellular mitochondrial oxygen consump-
tion was similar to the rate for untreated cells during the first
120 min of drug exposure:k ) 1.71 µM O2/min/106 cells in
the presence of 5µM doxorubicin and 1.92µM O2/min/106 cells
in the presence of 10µM doxorubicin. (The dark line in Figure
2A is a least-squares linear fit to the data for untreated cells,
and the two fainter lines are drawn parallel to the least-squares
fit line.) After 120-140 min, the value ofk in the presence of
5 µM doxorubicin declined to 1.23µM O2/min/106 cells (an
approximate 28% decrease from untreated cells), and in the
presence of 10µM doxorubicin, it declined to 0.56µM O2/
min/106 cells (an approximate 67% decrease from untreated
cells) (Figure 2A). Similar behavior was observed for cells
treated with 20 and 40µM doxorubicin (data not shown). For
t < 120 min, [O2] decreased linearly, withk ) 1.46 and 1.64
µM O2/min/106 cells, for 20 and 40µM, respectively. Fort >
140 min, we foundk ) 0.23 and 0.37µM O2/min/106 cells,
representing 84 and 77% decreases, respectively.
This inhibitory effect of doxorubicin on cellular respiration
was completely blocked by the presence of 20µM of the caspase
inhibitor zVAD-fmk (Figure 2B). Three repetitions of these
experiments consistently showed very similar results. For the
untreated cells in Figure 2B,k ) 2.55. For the treated cells,
k ) 1.49 for t > 120 min (an approximate 42% decrease from
untreated cells). With 20µM zVAD-fmk, the plot of [O2] vs t
was linear for all times, withk ) 2.36, essentially the same as
for untreated cells. Thus, the data show that caspase activities
mediate the effect of doxorubicin on mitochondria and that about
2 h is required to execute mitochondrial dysfunction.
The inhibitory effect of NaCN is shown in Figure 2C. The
value ofk in the presence of 10 mM NaCN was about 0.13µM
O2/min/106 cells. The value ofk after 120 min in the presence
of 20 µM doxorubicin was about 0.20µM O2/min/106 cells.
The value ofk in the presence of 20µM doxorubicin plus 10
mM NaCN was about 0.46µM O2/min/106 cells (Figure 2C).
The first two values were similar to the drift observed in the
control Pd phosphor solutions (without cells) containing 10 mM
NaCN alone (0.10µM O2 min-1) or 20µM doxorubicin (0.29
µM O2 min-1). Thus, NaCN completely inhibited respiration
in treated and untreated cells. Note thatk, when both cyanide
and doxorubicin were present, was approximately the sum ofk
in the presence of cyanide andk in the presence of doxorubicin.
Figure 3A shows the analysis of oxygen measurements on
106 cells/mL, either untreated or treated with 20 or 40µM
doxorubicin (as in Figure 2). Here, six-point segments (total
time 35 min, since measurements were made every 7 min) were
fitted to lines; the magnitude of the slope (k) with statistical
error is shown in Figure 3B-D, plotted against the start time
of the segment. Figure 3B is for no drug, Figure 3C is for 20
µM doxorubicin, and Figure 3D is for 40µM doxorubicin. In
the first case,k was constant, but in the presence of 20 or 40
µM drug, there was a sudden drop ink at about 150 min.
Another way to demonstrate the sudden drop in respiration
and also to comparek values for treated and untreated cells for
long treatment times involved the following experiment. Two
10 mL cultures of Jurkat cells were prepared; each contained
106 cells/mL, one with addition of 20µM doxorubicin and one
without the addition. Both samples were incubated at 37°C,
open to the air. Every hour, starting att ) 0, a 1 mLsample of
each was taken and placed in sealed vials for phosphorescence
measurement of [O2] in the usual way, alternating between the
two. One measurement was made per minute. Because more
than 10 min was required to load and equilibrate samples,
measurements could be made only∼15 min after taking a
sample. The results are shown in Figure 4A (open circles for
no drug and filled squares for 20µM drug). The set of [O2]
values for each sample was fitted to a line to obtaink. The k
values with statistical errors are plotted in Figure 4B. For
untreated cells,k was essentially constant, although it increased
Figure 3. Effects of doxorubicin on the respiration of 106 Jurkat cells in 1 mL total volume (sealed). (A) [O2] as a function oft for untreated cells
(empty squares), cells incubated with 20µM doxorubicin (gray circles), and cells incubated with 40µM doxorubicin (black triangles). Values of
k were derived by fitting six-point segments (corresponding to 35 min) of these plots to lines. (B) Derivedk values and statistical errors for no drug,
plotted vs segment start time. (C) Derivedk values and statistical errors for 20µM drug, plotted vs segment start time. (D) Derivedk values and
statistical errors for 40µM drug, plotted vs segment start time.
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slightly after the first point (as noted, doxorubicin may increase
the rate of respiration at early times). The value ofk for treated
cells was about the same as for untreated cells at early times
(first set of [O2] values) but dropped after 1 h and remained
constant thereafter, never decreasing to zero. Note that, because
drug was always present, the incubation time for the second
set of [O2] values was about 100 min. Thus, these experiments
show a sudden drop in respiration after about 100 min of
incubation. That this is less than previously found times (∼150
min) may be associated with the increased oxygen present.
We next evaluated the respiration of HL-60 cells in the
presence of 20µM doxorubicin, with and without 20µM zVAD-
fmk (Figure 5A). Oxygen consumption was unchanged during
the first 150 min of incubation with doxorubicin. The value of
k (in µM O2/min/106 cells) for untreated cells was 1.11; for
doxorubicin-treated cells (t < 150 min), k ) 1.22; and for
doxorubicin-treated cells with 20µM zVAD-fmk, k ) 1.21.
After 150 min of incubation, the value ofk for doxorubicin-
treated cells declined to 0.69 (about 43% inhibition). The value
of k in the presence of 10 mM NaCN was 0.03 (Figure 5A).
Thus, the effect of doxorubicin on HL-60 respiration was very
similar to its effect on Jurkat cells.
In HL-60/MX2 cells, the value ofk for untreated cells was
about 1.65µM O2/min/106 cells; for cells incubated with 20
µM doxorubicin, the value ofk was about 2.94µM O2/min/106
cells (a 1.8-fold increase); and for cells incubated with 20µM
doxorubicin plus 20µM zVAD-fmk, the value ofk was about
2.87 µM O2/min/106 cells (Figure 5B). These results were
consistently reproducible and demonstrated a lack of inhibition
of respiration in HL-60/MX2 cells during up to 4 h ofincubation
with 20 µM doxorubicin. The fact that inhibition of respiration
by doxorubicin was not observed in HL-60/MX2 cells, which
lack topoisomerase II activity, indicated that topoisomerase II
was required for doxorubicin-induced execution of apoptosis
and promotion of mitochondrial dysfunction. It also appears that
doxorubicin enhanced HL-60/MX2 respiration∼1.8-fold. This
drug effect was fully inhibited by cyanide or rotenone (not
shown). Thus, the enhancement was not mediated by redox
cycling of doxorubicin by mitochondria (6).
Luminescence Calibration.Cellular ATP was determined
from the luminescence vs time curve in the presence of luciferin
and luciferase. The observed luminescence as a function of time
should follow Re-γt + â, with R proportional to the initial
[ATP]. Attempts to fit our experimental data to this three-
parameter form were unsuccessful because the scatter in
measured intensities was a large fraction of the variation in light
intensity over 600 s, making the determination of three
parameters unreliable. (Typical intensity plots are shown in the
top panel of Figure 6.) Instead, we fit our data to the
two-parameter exponential formAe-kt, as shown in the top panel
of Figure 6, for which the exponential fits are 41.27 e-0.00035t
and 35.43 e-0.00042t. It is obvious that, ifR is much smaller than
â (very small [ATP]),k will approach 0, whereas ifR is much
larger thanâ (very large [ATP]),k will approachγ, the rate
constant for the ATP-luciferin reaction. For small [ATP], the
value ofk must be proportional toR/â, i.e., to the initial [ATP];
but for larger [ATP], the value ofk will approach a limiting
value.
This behavior is shown in the bottom panel of Figure 6, which
gives the results (k values) of fitting exponentials to lumines-
cence vs time data sets obtained for a series of solutions of
Figure 4. Effect of doxorubicin on the respiration of Jurkat cells. Two
cultures of 106 cells per mL were incubated at 37°C, one without drug
and one with 20µM doxorubicin. Every hour, samples of both cultures
were withdrawn for measurement of [O2]. (A) Measured [O2] vs t.
Circles, untreated cells; filled squares, drug-treated cells. (B) Values
of k derived from the results of A. For untreated cells,k increased
slightly after 1 h and remained constant thereafter; for treated cells,k
had the same value as for untreated cells initially but dropped markedly
after 1 h and remained constant thereafter.
Figure 5. Effects of doxorubicin on the respiration of HL-60 and HL-
60/MX2 cells. The cells were processed as described in the legend to
Figure 2. Minute zero corresponds to the addition of 20µM doxorubicin
to HL-60 (A) or HL-60/MX2 (B) cells. (A) Solid diamonds, untreated
cells with linear fit; triangles, treated cells with fit to two lines fort <
150 min andt > 150 min; light diamonds, treated cells plus 20µM
zVAD-fmk; and circles, cells plus 10 mM NaCN. (B) Diamonds,
untreated cells with linear fit; squares, treated cells with linear fit; and
triangles, treated cells plus zVAD-fmk.
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known [ATP] from 0 to 0.6µM. Three data sets were obtained
and analyzed for each [ATP]. In the bottom panel of Figure 6,
we plot the average value ofk with the standard deviation. (The
dashed curve is a fit to the analytic form,k ) a - be-c[ATP],
for clarity.) It is evident that one can measure [ATP] reliably
by our method only when [ATP] is less than 0.2µM. For
solutions of higher [ATP], it was required to dilute the sample
before measurement to make [ATP] less than 0.2µM. It should
be noted that the calibration against standard ATP solutions has
to be performed for each luciferin solution, because of variations
from one preparation to another, and the experimental measure-
ments should be done soon after calibration, because the solution
degrades in a few days.
Cellular ATP. Jurkat cells were suspended at 106 cells per
mL media with 10% fetal bovine serum and 1% albumin and
incubated at 37°C in sealed containers for up to 3 h. The results
of measurement of ATP are shown in Figure 7, as 100 times
the ratio of measured ATP at timet to measured ATP at time
0. Three conditions were used as follows: no addition of drug
(circles), with addition of 20µM doxorubicin (squares), and
with addition of 20 mM NaCN (triangles). At 1 h intervals after
addition of doxorubicin or cyanide, three 1 mL samples of each
cell suspension were taken for analysis of ATP. With no
addition, cellular ATP remained constant. The addition of
doxorubicin had no effect on cellular ATP at 1 h, but at 3 h,
ATP decreased to 36% of its initial value. The addition of
cyanide produced a sharp decrease in cellular ATP at 1 h and
a further decrease to 20% of its initial value at 3 h. For all three
conditions, there was a small increase in cellular ATP between
2 and 3 h; further investigation will be necessary to determine
whether this increase is significant.
A second series of experiments was designed to show the
effect of zVAD. Jurkat cells were suspended at 106 cells per
mL media with 10% fetal bovine serum and 1% albumin and
incubated at 37°C in containers open to the air for up to 5 h
(Figure 8). Three conditions were used as follows: untreated
(circles), addition of 20µM doxorubicin (dark squares) and
addition of 20 µM doxorubicin plus 20µM zVAD (light
squares). At time 0 and at five succeeding 1 h time intervals,
three samples were collected from each of the three conditions
and analyzed for ATP as described above. Each result shown
in Figure 8 is the mean of three values with standard deviations.
For untreated cells, ATP did not decrease during the 5 h period
and may even have increased (slope) 0.38 ( 0.18 nmol/106
cells/h). With 20µM doxorubicin, there was an overall decrease
of about 25% in cellular ATP. However, there was no apparent
effect for the first 3 h: The slope of the line fitted to the first
four points, shown as a dashed line in Figure 8, was actually
positive (0.66( 0.16 nmol/106 cells/h). After 3 h, cellular ATP
decreased rapidly (the slope of the linear fit to the last three
points was-2.4 ( 0.3 nmol/106 cells/h). With 20µM zVAD
Figure 6. Top panel: Plots of measured luminescence intensity L vs
t, with exponential fits [L ) A exp(-kt)], from which k values and
[ATP] are determined (see below). These results are for [ATP]) 0.10
µM. The best-fit exponentials, shown, are 41.27 e-0.00035t and 35.43
e-0.00042t. Bottom panel: Calibration curve for luminescence mea-
surement of ATP. Three solutions were prepared for each ATP
concentration indicated. Luminescence intensity as a function of time
was measured for each solution out to 600 s and fitted to the exponential
[A exp(-kt)]. Average values ofk and standard deviations are shown
for each concentration. The value ofk is linear in [ATP] for [ATP] <
0.15µM (the dashed curve is a fit tok ) b{1 - exp(-c[ATP]}); so,
for accurate determination of ATP, some solutions were diluted before
measurement.
Figure 7. Effect of doxorubicin on cellular ATP. Jurkat cells were
suspended at 106 cells per mL media, with 10% fetal bovine serum
and 1% albumin, and incubated at 37°C in sealed containers either
alone (open circles), with 20µM doxorubicin (squares), or with 20
mM NaCN (triangles). At indicated time points (t ) 0 corresponds to
the addition of doxorubicin or NaCN), three 1 mL samples of each
cell suspension were removed and processed for cellular ATP deter-
mination. ATP concentrations are given as percents of concentration
at t ) 0 (before incubation). Mean and standard deviations are shown
for each measurement.
Figure 8. Jurkat cells were suspended at 106 cells per mL media with
10% fetal bovine serum and 1% albumin and incubated at 37°C with
stirring in containers open to the air. Under these conditions of
incubation, stirring reintroduced oxygen into the suspension so the [O2]
of the cell suspension did not decrease witht. The reaction mixtures
contained no additions (circles), 20µM doxorubicin (dark squares), or
20 µM doxorubicin plus 20µM zVAD (light squares). At 1 h time
intervals, three samples of each condition were analyzed for ATP as
described. Mean [ATP], with standard deviations, is shown. The dashed
line is a linear fit to the first four points, showing that doxorubicin
treatment did not decrease cellular ATP during the first 3 h.
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added in addition to 20µM doxorubicin, cellular ATP did not
decrease with time. Indeed, cellular ATP increased slightly: The
slope was 0.59( 0.24 nmol/106 cells/h, equal (within statistical
error) to the slope for untreated cells and to the slope for
doxorubicin-treated cells fort e 3 h. It is clear that zVAD
nullifies the doxorubicin-induced attenuation of cellular ATP
as well as the doxorubicin-induced inhibition of respiration.
Discussion
Anthracyclines are known to target the mitochondria (4-7).
However, incubations of beef heart submitochondrial particles
with doxorubicin produced no noticeable effect on oxygen
consumption (17). Thus, the effect of this drug on cellular
respiration is likely indirect, perhaps mediated by induction of
apoptosis. We utilized zVAD-fmk (a pan-caspase family inhibi-
tor) (21) in order to investigate whether caspases mediate
doxorubicin’s effect on cellular respiration (Figures 2B and 5).
Resistant (HL-60/MX2) and sensitive (HL-60 and Jurkat) cells
were used to explore the role of topoisomerase II activity
(deficient in HL-60/MX2) in doxorubicin-induced mitochondrial
dysfunction. Cellular oxygen consumption (Figures 2-5) and
ATP content (Figures 7 and 8) were determined during
continuous exposure to doxorubicin. The presence of cyanide
in these experiments inhibited cellular respiration (Figures 2C
and 5A) and ATP content (Figure 8), thus establishing that both
processes occurred primarily in association with oxidations in
the respiratory chain.
The results show that doxorubicin induces apoptosis (activa-
tion of caspases), which impairs respiration. Thus, the decrease
in oxygen consumption is a consequence of apoptosis. The fact
that the combination of cyanide and doxorubicin leads to greater
oxygen consumption than with cyanide alone (Figure 2C)
suggests that doxorubicin may slightly stimulate oxygen con-
sumption, as shown previously (4, 5).
It has been reported that doxorubicin increased the perme-
ability of the inner mitochondrial membrane by opening the
mitochondrial PTP. In adenocarcinoma cells, doxorubicin (17
µM for 60 min) decreased the value of∆ψ by about 30%, an
effect that was blocked by zVAD-fmk (7). Such an effect on
∆ψ would be expected to uncouple phosphorylation from
oxidation. In addition, doxorubicin increases the permeability
of the outer mitochondrial membrane to cytochromec, an effect
that is expected to decrease mitochondrial respiration.
The inhibitory effect of doxorubicin on respiration, observed
in our experiments on Jurkat and HL-60 cells, was evident
within 2-3 h of incubation with the drug (Figures 2A,B and
5A). This inhibitory effect was blocked by zVAD-fmk (Figures
2B and 5A) and was not observed in HL-60/MX2 cells (Figure
5B), which lacked topoisomerase II activity. Thus, it is clear
from these observations that doxorubicin-induced inhibition of
respiration requires caspase and topoisomerase II activities.
The rate of respiration in cells exposed to the drug remains
close to the rate in untreated cells for about 2.5 h and then
decreases, remaining relatively constant thereafter. (For cells
exposed to the drug in the presence of air, the decrease ink
occurs sooner, at about 1.5 h, as seen in Figure 4. It is known
that drugs such as doxorubicin are more effective in inducing
apoptosis when oxygen is present, possibly because reactive
oxygen species play a role.) As will be shown in a future
publication, other apoptosis-inducing drugs (e.g., actinomycin
D) behave differently: They decrease respiration in Jurkat cells
gradually, starting at the earliest times for which measurements
can be made. The data in Figure 7 show that ATP levels do not
decrease for at least 1 h of the treatment, and a significant
decrease has occurred by 2 h, slightly earlier than for respiration.
Observations relevant to the role of mitochondrial∆ψ were
presented in a series of papers by Green and co-workers (22-
24) who examined the apoptotic response of HL-60 and other
cells following short exposures to actinomycin D, etoposide,
or staurosporine. It was found that apoptosis was initiated
without significant changes in∆ψ and the changes in∆ψ
occurred only later in the cell death pathway. The authors
concluded that collapse of∆ψ, resulting from formation of the
PTP, was not a critical feature of apoptosis (22). Studies of
single cells treated with etoposide or actinomycin D showed
that, if caspases were not activated, the mitochondria maintained
critical functions, such as the generation of ATP, even after
release of cytochromec (23). In contrast, caspase activation
disrupts complexes I-II of the mitochondrial electron transport
chain, resulting in diminished∆ψ and generation of reactive
oxygen species (24). The results in Figures 2 and 3 and Figures
7 and 8 agree with these reports and show that caspase activation
impairs oxidative phosphorylation. The decrease in cellular ATP
(Figures 7 and 8) also emphasizes the importance of mitochon-
drial death during apoptosis (11).
Mizutani et al. (25) found that incubation of HL-60 cells with
doxorubicin for up to 8 h led to H2O2-mediated oxidative
damage of DNA, which in turn led to an indirect generation of
H2O2 via activation of NAD(P)H oxidase. The end result was
an increase in∆ψ and activation of caspase-3. Doroshow (4)
reported that high concentrations of doxorubicin (135µM)
stimulated oxygen consumption when added to isolated cardiac
mitochondria. The stimulation was more readily demonstrable
in the presence of KCN and rotenone. The overall increase in
oxygen consumption was attributed to the production of
superoxide anion (5). The enhancement of O2 consumption was
immediate, required NADH, and was more pronounced in the
presence of rotenone or cyanide. It was concluded that mito-
chondrial NADH dehydrogenase reduced doxorubicin to its
semiquinone, with subsequent transfer of electrons to O2
(5-7).
The observation that oxygen consumption in the present
experiments was completely inhibited by NaCN (Figures 2C
and 5A) strongly supports the conclusion that the observed O2
consumption occurred in the mitochondrial respiratory chain.
If reactive oxygen species were produced, their amounts did
not significantly add to the observed respiration. It is also
unlikely that small amounts of reactive oxygen intermediates
were responsible for the observed inhibition of respiration and
lowering of ATP levels since the effects of doxorubicin were
prevented when zVAD-fmk was included in incubation mix-
tures. Thus, it is clear that, in our experiments, doxorubicin
treatment executed apoptosis within about 2 h ofdrug exposure,
decreasing mitochondrial oxidative phosphorylation (Figures
2-4 and 8). Furthermore, the decline in cellular ATP contributed
to the mechanism of cell death by apoptosis (Figures 7 and 8).
It is worth noting that the doxorubicin-induced cellular ATP
depletion started earlier and was more pronounced in the sealed
vials (Figure 7) than the open containers (Figure 8).
In summary, the results presented show that cells exposed to
doxorubicin exhibit partial, dose-dependent inhibition of oxida-
tive phosphorylation. The inhibition occurs after a few hours
of exposure to the drug, is mediated by caspases, and requires
topoisomerase II activity.
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